Saberscope can be used in diagnostic and therapeutic procedures for endoscopy and endoscopic surgery within the thoracic and peritoneal cavities. Credit: BIld av oracast from Pixabay.

Medical devices maker Xenocor has received $10m in Series A financing to support the launch and rapid adoption of its 5mm articulating and single-use laparoscope system, Saberscope.

Led by GenHenn Venture Fund I, the funding round also involved Barvest Ventures, Baranco Investments and Patel Family Investments as participants.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Saberscope system is designed for use in endoscopy and endoscopic surgery within the thoracic and peritoneal cavities including the female reproductive organs.

The system is already approved by the US Food and Drug Administration (FDA) for use in laparoscopic and thoracoscopic surgery.

Xenocor CEO Charles DeCoster IV said: “Xenocor is laser-focused on facilitating the evolution of the 35-year-old laparoscopic visualisation model to something that clearly better serves caregivers and patients during minimally invasive surgery.

“Our FDA-cleared Saberscope improves visualisation, dramatically diminishes workflow complexity, increases safety and reduces waste.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Planned to be launched this year, the Saberscope helps to phase out fog and improves visualisation for the surgeon through smoke and steam.

With the ability to articulate 90° in any direction, the device provides surgeons with a full view of the anatomy at any point during the procedure.

The non-conducting system does not get too hot to initiate combustion. It can also fit in a Xenocor recycle bin and can be replaced with a new one.

Michael Hennessy Jr from GenHenn Capital will join Xenocor’s board of directors to support the growth of the company. In August last year, Xenocor received patent protection for the Saberscope system from the United States Patent and Trademark Office.